In the case of Alzheimer's disease (AD), complement activation, inflammation, and glial cell activation have long been recognized as features of the disease, albeit considered secondary to amyloid‐β (Aβ) and tau‐related pathology;3 however, recent genetic studies suggest that complement plays a primary role in AD. This evidence concerns the gene MAPT and Alzheimer disease.